KR20230121761A - 인테그린 억제제 및 그의 용도 - Google Patents

인테그린 억제제 및 그의 용도 Download PDF

Info

Publication number
KR20230121761A
KR20230121761A KR1020237020570A KR20237020570A KR20230121761A KR 20230121761 A KR20230121761 A KR 20230121761A KR 1020237020570 A KR1020237020570 A KR 1020237020570A KR 20237020570 A KR20237020570 A KR 20237020570A KR 20230121761 A KR20230121761 A KR 20230121761A
Authority
KR
South Korea
Prior art keywords
crystalline form
weight
degrees
water content
theta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020237020570A
Other languages
English (en)
Korean (ko)
Inventor
제이컵 차
카테리나 레프테리스
가오 치
졘 왕
?? 왕
다롄 자오
Original Assignee
플라이언트 테라퓨틱스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 플라이언트 테라퓨틱스, 인크. filed Critical 플라이언트 테라퓨틱스, 인크.
Publication of KR20230121761A publication Critical patent/KR20230121761A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/33—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems
    • C07C309/34—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems formed by two rings
    • C07C309/35—Naphthalene sulfonic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020237020570A 2020-11-19 2021-11-19 인테그린 억제제 및 그의 용도 Withdrawn KR20230121761A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063116042P 2020-11-19 2020-11-19
US63/116,042 2020-11-19
PCT/US2021/072510 WO2022109598A1 (en) 2020-11-19 2021-11-19 Integrin inhibitor and uses thereof

Publications (1)

Publication Number Publication Date
KR20230121761A true KR20230121761A (ko) 2023-08-21

Family

ID=81709878

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237020570A Withdrawn KR20230121761A (ko) 2020-11-19 2021-11-19 인테그린 억제제 및 그의 용도

Country Status (19)

Country Link
US (2) US12018025B2 (https=)
EP (1) EP4247472A4 (https=)
JP (1) JP2023550428A (https=)
KR (1) KR20230121761A (https=)
CN (1) CN116710169A (https=)
AU (1) AU2021381516A1 (https=)
CA (1) CA3173755A1 (https=)
CL (1) CL2023001418A1 (https=)
CO (1) CO2023006522A2 (https=)
CR (1) CR20230262A (https=)
CU (1) CU20230026A7 (https=)
DO (1) DOP2023000101A (https=)
EC (1) ECSP23045278A (https=)
IL (1) IL302651A (https=)
JO (1) JOP20230102A1 (https=)
MX (1) MX2023005889A (https=)
PE (1) PE20240114A1 (https=)
TW (1) TW202235417A (https=)
WO (1) WO2022109598A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10696672B2 (en) 2016-12-23 2020-06-30 Pliant Therapeutics, Inc. Amino acid compounds and methods of use
TWI841573B (zh) 2018-06-27 2024-05-11 美商普萊恩醫療公司 具有未分支連接子之胺基酸化合物及使用方法
CN114173803A (zh) 2019-04-08 2022-03-11 普利安特治疗公司 氨基酸化合物的剂型和方案
CN120091811A (zh) * 2022-07-09 2025-06-03 普利安特治疗公司 整合素抑制剂及其与其它药剂组合的用途
WO2024155965A2 (en) * 2023-01-21 2024-07-25 Pliant Therapeutics, Inc. Biomarkers for use in integrin inhibitor therapy
WO2025072206A1 (en) * 2023-09-25 2025-04-03 Pliant Therapeutics, Inc. Integrin inhibitors for treatment of primary sclerosing cholangitis
US20250197393A1 (en) 2023-12-14 2025-06-19 Pliant Therapeutics, Inc. Integrin inhibitor and uses thereof
WO2025217571A1 (en) * 2024-04-12 2025-10-16 Pliant Therapeutics, Inc. Fixed dose combinations of integrin inhibitor with ppar agonists

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210033067A (ko) * 2012-06-04 2021-03-25 파마싸이클릭스 엘엘씨 브루톤 타이로신 키나아제 저해제의 결정 형태
WO2015048819A1 (en) 2013-09-30 2015-04-02 The Regents Of The University Of California Anti-alphavbeta1 integrin compounds and methods
WO2016145258A1 (en) 2015-03-10 2016-09-15 The Regents Of The University Of California Anti-alphavbeta1 integrin inhibitors and methods of use
EP3509590A4 (en) 2016-09-07 2020-12-02 Pliant Therapeutics, Inc. N-ACYL AMINO ACID COMPOUNDS AND METHODS OF USE
US10696672B2 (en) 2016-12-23 2020-06-30 Pliant Therapeutics, Inc. Amino acid compounds and methods of use
MX394210B (es) 2017-02-28 2025-03-04 Morphic Therapeutic Inc INHIBIDORES DE INTEGRINA AVß6.
MA52117A (fr) 2017-02-28 2022-04-06 Morphic Therapeutic Inc Inhibiteurs de l'intégrine (alpha-v) (bêta-6)
FI3761980T3 (fi) * 2018-03-07 2024-02-21 Pliant Therapeutics Inc Aminohappoyhdisteitä ja käyttömenetelmiä
TWI841573B (zh) 2018-06-27 2024-05-11 美商普萊恩醫療公司 具有未分支連接子之胺基酸化合物及使用方法
WO2020016704A1 (ja) * 2018-07-20 2020-01-23 株式会社半導体エネルギー研究所 撮像パネル、撮像装置
WO2020047207A1 (en) 2018-08-29 2020-03-05 Morphic Therapeutics, Inc. Inhibitors of (alpha-v)(beta-6) integrin
WO2020047239A1 (en) 2018-08-29 2020-03-05 Morphic Therapeutic, Inc. INHIBITING αV β6 INTEGRIN
WO2020047208A1 (en) 2018-08-29 2020-03-05 Morphic Therapeutic, Inc. Inhibitors of (alpha-v)(beta-6) integrin
TW202028179A (zh) 2018-10-08 2020-08-01 美商普萊恩醫療公司 胺基酸化合物及使用方法
WO2020139379A1 (en) * 2018-12-28 2020-07-02 LunaPBC Community data aggregation, completion, correction, and use
US11730144B2 (en) * 2019-02-15 2023-08-22 Clean Bite, Llc Oral hygiene appliance
CN114173803A (zh) * 2019-04-08 2022-03-11 普利安特治疗公司 氨基酸化合物的剂型和方案
WO2021097338A1 (en) 2019-11-15 2021-05-20 Pliant Therapeutics, Inc. Compositions and methods for activation of integrins
CN115989235A (zh) * 2020-05-07 2023-04-18 普利安特治疗公司 使用氨基酸化合物治疗呼吸系统疾病的方法
TWI843503B (zh) * 2020-06-03 2024-05-21 美商基利科學股份有限公司 Lpa受體拮抗劑及其用途
WO2022087224A1 (en) * 2020-10-21 2022-04-28 Cohbar, Inc. Method of treating fibrosis with a combination therapy
MX2023012794A (es) 2021-04-30 2023-12-15 Pliant Therapeutics Inc Regímenes de dosificación expandidos para inhibidores de integrina.
US20240350494A1 (en) 2021-09-03 2024-10-24 Pliant Therapeutics, Inc. Therapeutic modulation of integrins
TW202329973A (zh) 2021-10-14 2023-08-01 美商普萊恩醫療公司 整合素抑制劑及其與其他藥劑併用之用途
JP2025518533A (ja) 2022-05-18 2025-06-17 プライアント・セラピューティクス・インコーポレイテッド インテグリン阻害剤の安定化

Also Published As

Publication number Publication date
CA3173755A1 (en) 2022-05-27
AU2021381516A9 (en) 2024-10-24
DOP2023000101A (es) 2023-09-29
MX2023005889A (es) 2023-06-06
US20220177468A1 (en) 2022-06-09
CR20230262A (es) 2023-07-26
EP4247472A1 (en) 2023-09-27
EP4247472A4 (en) 2024-10-09
CL2023001418A1 (es) 2023-10-30
ECSP23045278A (es) 2023-07-31
JOP20230102A1 (ar) 2023-05-08
CO2023006522A2 (es) 2023-06-09
US12018025B2 (en) 2024-06-25
WO2022109598A1 (en) 2022-05-27
TW202235417A (zh) 2022-09-16
CU20230026A7 (es) 2024-01-10
JP2023550428A (ja) 2023-12-01
IL302651A (en) 2023-07-01
US20240391914A1 (en) 2024-11-28
AU2021381516A1 (en) 2023-06-22
PE20240114A1 (es) 2024-01-22
CN116710169A (zh) 2023-09-05

Similar Documents

Publication Publication Date Title
KR20230121761A (ko) 인테그린 억제제 및 그의 용도
ES3014022T3 (en) Angiotensin ii receptor antagonist metabolite and nep inhibitor composite, and preparation method thereof
JP5315253B2 (ja) ラセミ型イラプラゾールの固体形
KR20210013554A (ko) Tlr7/tlr8 억제제의 결정질 형태
CN106414416A (zh) 结晶型ARB‑NEPi复合物及其制备方法和应用
TW201335161A (zh) 二氫吡咯并［１，２－ｃ］咪唑基皮質醛酮素合成酶或芳族酶抑制劑之新穎型式及鹽
CN103221049B (zh) 阿瑞匹坦l-脯氨酸组合物和共晶
WO2019033969A1 (zh) 替米沙坦与氢氯噻嗪的共晶
CN102958926A (zh) 作为抗组胺剂的卢帕他定盐
CN108203449A (zh) 一种新型可逆性质子泵抑制剂及其制备方法和用途
CN104447682A (zh) 比拉斯汀化合物
ES2463190B1 (es) Formas cristalinas de sartanes tales como telmisartán con betabloqueantes
CN106928218A (zh) 吗啉衍生物的盐及其晶型、其制备方法及药物组合物、用途
US20240294521A1 (en) Crystalline forms, compositions containing same, and methods of their use
WO2025124537A1 (en) Integrin inhibitor and uses thereof
JP7357634B2 (ja) Ｕｒａｔ－１阻害剤の新規塩型
KR20070087606A (ko) 인자 ｘａ 억제제의 결정질 형태
US7655800B2 (en) Crystalline 1H-imidazo[4,5-b]pyridin-5-amine, 7-[5-[(cyclohexylmethylamino)-methyl]-1H-indol-2-yl]-2-methyl, sulfate (1:1), trihydrate and its pharmaceutical uses
CN105367622B (zh) 一种阿加曲班化合物
BR102023008236A2 (pt) Forma sólida cristalina à base de hidralazina e furosemida, composição farmacêutica, kit e uso relacionado
CN120271560A (zh) 一种吡咯磺酰胺类抑酸剂的盐型及其制备方法和应用
BRPI0611096A2 (pt) (5z)-5-(6-quinoxalinilmetilideno)-2-[(2,6-diclorofenil)a mino]-1,3-tiazol-4(5h)-ona
HK40117473A (zh) 活化素受体样激酶抑制剂的盐和晶体形式
HK40069001B (zh) 活化素受体样激酶抑制剂的盐和晶体形式
CN114591260A (zh) 一种莫沙必利有机酸盐

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

B11 Application withdrawn

Free format text: ST27 STATUS EVENT CODE: N-1-6-B10-B11-NAP-PC1202 (AS PROVIDED BY THE NATIONAL OFFICE)

PC1202 Submission of document of withdrawal before decision of registration

St.27 status event code: N-1-6-B10-B11-nap-PC1202